Muhammad Tahir Aleem | Health Sciences | Best Researcher Award

Dr. Muhammad Tahir Aleem | Health Sciences | Best Researcher Award 

Shantou University Medical College | China

Dr. Muhammad Tahir Aleem is a highly accomplished early-career scientist in the field of Preventive Veterinary Medicine and Molecular Parasitology, with a multidisciplinary research background spanning veterinary sciences, immunology, molecular biology, vaccine development, and zoonotic diseases. He holds a Doctor of Veterinary Medicine (DVM) and an M.Phil. in Parasitology from the University of Agriculture, Faisalabad, Pakistan, and earned his Ph.D. from Nanjing Agricultural University, China, where his doctoral research focused on the role of progesterone receptors in the reproduction of Trichinella spiralis, a key area in parasite biology. He completed two postdoctoral fellowships: one in Molecular Parasitology and Chromosome Biology at Cleveland State University, USA, and another in Basic Medicine at Shantou University Medical College, China. Dr. Aleem has authored over 15 peer-reviewed articles, including several in Q1 journals such as Vaccines, International Immunopharmacology, and Biomedical Research International, contributing to a cumulative impact factor exceeding 148.14. His studies delve into advanced vaccine design (mRNA, DNA), host-parasite interactions, immunomodulation, and molecular docking techniques, reflecting a strong command of both theoretical and applied biomedical sciences. He has served as corresponding author on multiple publications, highlighting his leadership in collaborative research. His work has garnered over 400 citations, with an estimated h-index of 8–10, showcasing his growing impact in the international scientific community. Dr. Aleem’s research has far-reaching implications for both veterinary and human health, especially in the control of parasitic diseases, emerging zoonoses, and infectious disease prevention. He actively collaborates across institutions and countries, demonstrating a global outlook and commitment to scientific innovation. His contributions to membrane-associated progesterone receptor studies have opened new avenues for reproductive parasitology, while his recent work on mRNA and DNA vaccine platforms marks him as a forward-looking investigator. He also contributes to public health and translational medicine by addressing environmental pathogens and drug development challenges. Given his high-impact publications, international collaborations, cross-disciplinary research profile, and growing citation footprint, Dr. Muhammad Tahir Aleem stands out as a promising and deserving candidate for the Best Researcher Award. His work not only advances veterinary and biomedical sciences but also paves the way for translational solutions to global health challenges.

Profiles: Scopus | Google Scholar

Featured Publications

COVIDSurg Collaborative, & GlobalSurg Collaborative. (2021). Timing of surgery following SARS‐CoV‐2 infection: An international prospective cohort study. Anaesthesia, 76(6), 748–758.

Sohail, M. U., Ijaz, A., Yousaf, M. S., Ashraf, K., Zaneb, H., Aleem, M., & Rehman, H. (2010). Alleviation of cyclic heat stress in broilers by dietary supplementation of mannan-oligosaccharide and Lactobacillus-based probiotic: Dynamics of cortisol, thyroid hormones and growth performance. Poultry Science, 89(9), 1934–1938.

Suleria, H. A. R., Butt, M. S., Khalid, N., Sultan, S., Raza, A., Aleem, M., & Abbas, M. (2015). Garlic (Allium sativum): Diet based therapy of 21st century – A review. Asian Pacific Journal of Tropical Disease, 5(4), 271–278.

Ijaz, A., Hussain, A., Aleem, M., Yousaf, M. S., & Rehman, H. (2009). Butylated hydroxytoluene inclusion in semen extender improves the post-thawed semen quality of Nili-Ravi buffalo (Bubalus bubalis). Theriogenology, 71(8), 1326–1329.

Sultan, S., Huma, N., Butt, M. S., Aleem, M., & Abbas, M. (2018). Therapeutic potential of dairy bioactive peptides: A contemporary perspective. Critical Reviews in Food Science and Nutrition, 58(1), 105–115.

Jamil, M., Aleem, M. T., Shaukat, A., Khan, A., Mohsin, M., Rehman, T. U., Abbas, R. Z., Saleemi, M. K., Khatoon, A., Babar, W., Yan, R., & Li, K. (2022). Medicinal plants as an alternative to control poultry parasitic diseases. Life, 12(3), 449.

Adeel, M., Ijaz, A., Aleem, M., Rehman, H., Yousaf, M. S., & Jabbar, M. A. (2009). Improvement of liquid and frozen-thawed semen quality of Nili-Ravi buffalo bulls (Bubalus bubalis) through supplementation of fat. Theriogenology, 71(8), 1220–1225.

COVIDSurg Collaborative, GlobalSurg Collaborative, Nepogodiev, D., et al. (2022). SARS‐CoV‐2 infection and venous thromboembolism after surgery: An international prospective cohort study. Anaesthesia, 77(1), 28–39.

Bajwa, H. U. R., Khan, M. K., Abbas, Z., Riaz, R., Rehman, T., Abbas, R. Z., Aleem, M. T., et al. (2022). Nanoparticles: Synthesis and their role as potential drug candidates for the treatment of parasitic diseases. Life, 12(5), 750.

Farooq, M., Durrani, F. R., Aleem, M., Chand, N., & Muqarrab, A. K. (2001). Egg traits and hatching performance of Desi, Fayumi and Rhode Island Red chicken. Pakistan Journal of Biological Sciences, 4(7), 909–911.

 

Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Sankalchand Patel University Visnagar,Badoda | India

Mr. Jitendra Hilal Patil, Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, is a PCI-registered academic with a strong background in pharmaceutical sciences and nanotechnology. He holds an M.Pharm in Quality Assurance and is pursuing his Ph.D. at Sankalchand Patel University, Visnagar. His research focuses on developing pH-responsive nanocarrier drug delivery systems for targeted cancer therapy, with publications in Scopus-indexed journals and one patent under process. With a citation index of 29, his innovative work contributes significantly to advancing precision medicine while minimizing systemic toxicity in anticancer treatments.

Author Profile 

Scopus

Education

From the very beginning of his educational journey, Mr. Jitendra Hilal Patil demonstrated a keen interest in pharmaceutical sciences and biomedical research. His strong academic foundation was built through consistent excellence across secondary and higher secondary education, which he pursued with dedication and discipline. His pursuit of a Bachelor’s and Master’s degree in Pharmacy further sharpened his knowledge in drug formulation, quality assurance, and advanced pharmaceutical principles. These formative academic years not only shaped his scientific mindset but also ignited his passion for research in nanotechnology and innovative drug delivery systems. His pursuit of a Ph.D. reflects his commitment to expanding the boundaries of knowledge and contributing to global healthcare challenges.

Experience

Mr. Patil serves as a Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, where he plays a pivotal role in nurturing future pharmacists and researchers. His teaching approach integrates theory with practical insights, encouraging students to think critically about real-world healthcare challenges. Alongside his teaching responsibilities, he actively engages in research, ensuring his academic contributions are aligned with the latest developments in pharmaceutical innovation. His ability to balance teaching, research, and mentoring highlights his versatility as both an educator and a researcher. He also ensures his students are exposed to cutting-edge topics such as nanotechnology, targeted therapies, and drug delivery systems, preparing them to excel in the evolving landscape of pharmaceutical sciences.

Research Focus

The hallmark of Mr. Patil’s academic journey lies in his research on pH-responsive nanocarrier drug delivery systems designed for targeted cancer treatment. Recognizing the limitations of conventional chemotherapy—such as poor survival rates, systemic toxicity, and severe side effects—he focused on developing titanium-based metal-organic frameworks (Ti-MOFs) as nanocarriers for the anticancer drug axitinib (AXT).

Through advanced hydrothermal synthesis and characterization techniques, he successfully developed stable, porous nanostructures that exhibit excellent pH-responsive behavior. His in vitro studies revealed that these carriers released minimal drug amounts in neutral pH, simulating healthy tissues, but significantly increased release in acidic environments mimicking cancer cells. This innovation represents a major step toward precision medicine, offering the potential to reduce toxicity and enhance therapeutic efficacy. His work exemplifies how nanotechnology can transform oncology treatments, opening doors to more effective and patient-friendly therapies.

Awards and Recognition

Mr. Patil’s research has garnered recognition through Scopus-indexed publications, citations, and a patent under process, highlighting the originality and applicability of his work. With a citation index of 29, his publications demonstrate a meaningful academic impact and a growing influence in the pharmaceutical research community. He is also a registered member of the Pharmacy Council of India (PCI), further strengthening his professional credibility. While he has not yet accumulated multiple industry consultancy projects or editorial appointments, his promising work and contributions reflect the qualities of a rising researcher who is set to achieve even greater recognition at both national and international levels.

Impact and Influence

The potential impact of Mr. Patil’s research extends beyond academia, offering transformative possibilities in cancer treatment. By addressing the challenges of drug toxicity and inefficient targeting, his nanocarrier-based system has the potential to improve the quality of life for patients undergoing therapy. Moreover, his contributions set a strong foundation for future collaborations in nanomedicine, oncology research, and pharmaceutical technology. His influence also extends to his students, who benefit from his mentorship, guidance, and emphasis on research-driven learning. By bridging the gap between classroom knowledge and practical innovation, he inspires a new generation of pharmaceutical professionals to pursue impactful research that addresses pressing healthcare challenges.

Publications

Nonlocal thermoelastic diffusion analysis in a semi-infinite body subjected to thermal loading with memory effects.

Author: Jitendra Patil, Chandrakant Jadhav, Nitin Chandel & Vinod Varghese
Journal: Archive of Applied Mechanics
Year: 2025

Development and Characterization of AXT@Metal-Organic Framework: A Biocompatible, pH-Responsive Nanocarrier for Targeted Axitinib Delivery in MCF-7 Cancer Cells.

Author: Jayvadan K. Patel, Ujashkumar A. Shah, Pravin O. Patil, Jitendra H. Patil
Journal: Annales Pharmaceutiques Françaises
Year: 2025

Conclusion

Mr. Jitendra Hilal Patil exemplifies the qualities of a dedicated educator, an emerging researcher, and an innovator in pharmaceutical sciences. His academic journey, professional commitments, and research on pH-responsive nanocarriers reflect not only his scientific expertise but also his vision for improving global healthcare outcomes. With a growing body of impactful publications, a patent under process, and recognition as a promising voice in nanotechnology and drug delivery research, he continues to inspire both peers and students alike. Looking forward, his unwavering dedication positions him to make enduring contributions that bridge cutting-edge research with tangible benefits for society, leaving a meaningful legacy in academia and beyond.

Cheng Ni | Health Sciences | Best Researcher Award | 13442

Prof. Cheng Ni | Health Sciences | Best Researcher Award

Prof. Cheng Ni, Cancer Hospital, Chinese Academy of Medical Sciences, China

Prof. Cheng Ni, M.D., Ph.D. is a Professor and Consultant Anesthesiologist at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, where he also serves as Associate Chief of the Department of Anesthesiology. With extensive clinical and academic experience in thoracic anesthesiology, perioperative neuroprotection, and cancer pain management, Prof. Ni has held key roles at leading institutions including Peking University and Harvard University. His research focuses on perioperative neurocognitive disorders, tumor immunology, and the application of AI in anesthesiology. He has published over 50 SCI-indexed articles and holds 11 authorized patents.

Profile

Scopus

🎓 Early Academic Pursuits

Prof. Cheng Ni’s academic journey is a testament to dedication and intellectual rigor. He began his medical education at Capital Medical University, earning his M.D. in 2003 and M.S. in 2005, laying a solid foundation in medical sciences. His passion for deeper understanding and specialization led him to pursue a Ph.D. at Peking University, one of China’s most prestigious institutions, which he completed in 2012. This advanced academic training equipped him with a rich knowledge base in anesthesiology and related biomedical sciences, paving the way for a distinguished career in clinical practice, teaching, and research.

🩺 Professional Endeavors

Prof. Ni’s professional career reflects a steady and impactful rise through China’s top-tier medical institutions. He began as a Resident at Peking University Third Hospital (2005–2008) and subsequently served as an Attending Anesthesiologist (2008–2015). During this period, he gained hands-on clinical experience and honed his leadership abilities.

In 2013–2014, he expanded his global perspective as a Postdoctoral Research Fellow at Harvard University, engaging with cutting-edge international research. Upon his return, he held several key administrative and academic roles at Peking University, including Chief Secretary of the Faculty of Anesthesiology, and Associate Consultant and Associate Professor.

In 2020, Prof. Ni joined the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, a top national institution, as a Consultant and Associate Professor. His expertise quickly earned him leadership roles as Associate Chief of the Department of Anesthesiology, and by 2021, he was promoted to Professor and Consultant. He also became a Ph.D. Supervisor in 2023, mentoring the next generation of clinical researchers and specialists.

🔬 Contributions and Research Focus

Prof. Ni’s research contributions span multiple high-impact areas in modern anesthesiology and cancer care. His primary interests include:

  • Perioperative neurocognitive disorders 🧠

  • Thoracic anesthesiology and neuroprotection 💨🛡️

  • Cancer pain management 🧬

  • Genetics and tumor immunology 🧫

  • AI in anesthesiology research 🤖🩺

He has authored over 50 peer-reviewed articles in leading SCI-indexed journals, including Aging Cell, CNS Neuroscience & Therapeutics, Life Sciences, and Anesthesia & Analgesia. His recent publications explore the neuroinflammatory response during surgery, the effects of anesthesia on brain aging, and the integration of hybrid learning models for brain cell identification—blending medical science with artificial intelligence.

In addition to journal publications, Prof. Ni has contributed to 12 academic monographs and holds 11 authorized patents, underscoring his commitment to translational research and innovation.

🏅 Accolades and Recognition

Prof. Cheng Ni is widely respected in China’s medical and academic communities. His achievements have been recognized through his appointment to senior roles such as:

  • Chief Secretary of Anesthesiology Faculty, Peking University Health Science Center

  • Associate Chief of the Department of Anesthesiology at China’s National Cancer Center

  • Ph.D. Supervisor, guiding graduate-level research and fostering academic excellence

These appointments are not only acknowledgments of his skill and dedication but also affirmations of his influence in shaping anesthesiology and cancer care practices in China.

🌍 Impact and Influence

Prof. Ni’s work resonates far beyond the operating room. His integration of AI into anesthesiology research marks a forward-thinking approach to modern medicine. By exploring the cognitive effects of anesthesia, he contributes to improving surgical outcomes and patient safety, particularly in aging populations.

His leadership and mentorship roles at premier institutions like Peking University and the Cancer Hospital, CAMS, have helped nurture a generation of professionals equipped with both technical excellence and ethical insight.

Furthermore, his international collaboration with Harvard University has brought valuable cross-cultural research experience into Chinese clinical research settings, promoting a global standard in anesthesiology and perioperative medicine.

🌱 Legacy and Future Contributions

Looking ahead, Prof. Ni is poised to play a pivotal role in shaping the future of anesthesiology in cancer care. His continued emphasis on neuroprotection, chronic pain management, and artificial intelligence applications signals a progressive vision aligned with global health priorities.

As a Ph.D. supervisor and seasoned educator, his mentorship will continue to inspire emerging scholars. His innovations in clinical protocols and diagnostic tools will likely set new benchmarks in anesthetic safety and cancer patient recovery.

Prof. Cheng Ni stands as a bridge between tradition and innovation, combining deep clinical knowledge with research excellence to lead transformative change in anesthesiology and oncology care.

Publication Top Notes

Author: Z., Suo, Zizheng, T., Xiao, Ting, Y., Qu, Yinyin, H., Zheng, Hui, C., Ni, Cheng

Year: 2024